A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab.
Chantal MathieuAlice E WiedemanKaren CerosalettiSarah Alice LongElisavet SertiLaura CooneyJoan VermeirenSilvia CaluwaertsKarolien Van HuynegemLothar SteidlerSven BlommePieter RottiersGerald T NepomKevan C Heroldnull nullPublished in: Diabetologia (2023)
ClinicalTrials.gov NCT03751007, EudraCT 2017-002871-24 FUNDING: This study was funded by Precigen ActoBio.
Keyphrases
- open label
- clinical trial
- double blind
- phase ii
- phase iii
- type diabetes
- study protocol
- placebo controlled
- phase ii study
- endothelial cells
- cardiovascular disease
- randomized controlled trial
- quantum dots
- insulin resistance
- adipose tissue
- combination therapy
- squamous cell carcinoma
- glycemic control
- pluripotent stem cells